Access to anti-retroviral drugs, male in IDA total

IDA total: Access to anti-retroviral drugs, male was 78.2% in 2024. ◆ Volatile

Latest (2024)
78.2%
Change on year
up 4.9%
Rank
11th
of 19 groups
All-time high
78.2%
in 2024
All-time low
0.0%
in 2000
Years of data
25
2000–2024

Access to anti-retroviral drugs, male in IDA total, 2000–2024

0204060802000201220242000: 0 %2001: 0.072 %2002: 0.094 %2003: 0.439 %2004: 1.8 %2005: 3.7 %2006: 6.7 %2007: 10.3 %2008: 14.6 %2009: 18.7 %2010: 21.9 %2011: 24.8 %2012: 27.8 %2013: 32.1 %2014: 36.3 %2015: 40.8 %2016: 45.5 %2017: 51.3 %2018: 54.5 %2019: 59.1 %2020: 63.9 %2021: 67.3 %2022: 71.7 %2023: 74.5 %2024: 78.2 %

Source: UNAIDS estimates. Measured in %.

Analysis

In 2024, access to anti-retroviral drugs, male in IDA total stood at 78.2%. That is the highest value across all 25 years on record.

That represents a change of up 4.9% on the previous year and up 115.5% over ten years.

Over the whole period, access to anti-retroviral drugs, male in IDA total peaked at 78.2% in 2024 and was at its lowest, 0.0%, in 2000.

The series is highly variable year to year, so single readings are best treated with caution.

Access to anti-retroviral drugs, male in IDA total, year by year

Annual values for Access to anti-retroviral drugs, male (%) in IDA total, 2000 to 2024.
Year % Change
2000 0.0%
2001 0.1%
2002 0.1% +30.0%
2003 0.4% +366.0%
2004 1.8% +305.5%
2005 3.7% +107.9%
2006 6.7% +81.2%
2007 10.3% +54.0%
2008 14.6% +41.2%
2009 18.7% +28.5%
2010 21.9% +17.0%
2011 24.8% +13.2%
2012 27.8% +12.0%
2013 32.1% +15.7%
2014 36.3% +12.9%
2015 40.8% +12.5%
2016 45.5% +11.6%
2017 51.3% +12.8%
2018 54.5% +6.1%
2019 59.1% +8.6%
2020 63.9% +8.0%
2021 67.3% +5.4%
2022 71.7% +6.6%
2023 74.5% +3.9%
2024 78.2% +4.9%

Averages by decade

DecadeAverage LowestHighest Years
2000s 5.6% 0.0% 18.7% 10
2010s 39.4% 21.9% 59.1% 10
2020s 71.1% 63.9% 78.2% 5

Countries ranked near IDA total

  1. 11 Botswana 92.0% compare
  2. 12 Spain 91.0% compare
  3. 13 Burundi 90.0% compare
  4. 13 Malawi 90.0% compare
  5. 13 Namibia 90.0% compare
  6. 13 Switzerland 90.0% compare

See the full ranking of 160 places →

More gender data for IDA total

All data for IDA total →

Frequently asked questions

What is access to anti-retroviral drugs, male in IDA total?
Access to anti-retroviral drugs, male in IDA total was 78.2% in 2024, according to UNAIDS estimates.
What is the highest access to anti-retroviral drugs, male recorded in IDA total?
The highest recorded value was 78.2% in 2024.
What is the lowest access to anti-retroviral drugs, male recorded in IDA total?
The lowest recorded value was 0.0% in 2000.
How does IDA total rank for access to anti-retroviral drugs, male?
IDA total ranks 11th out of 19 groups with data for 2024.
Is access to anti-retroviral drugs, male rising or falling in IDA total?
Over the last ten years it is up 115.5%. The long-run trend across the full record is volatile.
Where does this IDA total data come from?
The figures come from UNAIDS estimates, published as part of Access to anti-retroviral drugs, male (%). Statizoid updates them automatically from the source API.

Download this data

CSV · JSON — 25 observations, free to reuse under CC BY 4.0 (World Bank Open Data).

Share, cite or embed this page

Cite this page

Access to anti-retroviral drugs, male in IDA total. Statizoid, drawing on UNAIDS estimates. Retrieved 11 September 2026, from https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/ida-total/

Embed or link this data

Paste this into a page to link back to these figures. The data itself is free to reuse under CC BY 4.0 (World Bank Open Data); please keep the attribution.

<a href="https://gender.statizoid.com/stat/access-to-anti-retroviral-drugs-male-percent/ida-total/">Access to anti-retroviral drugs, male in IDA total</a> — Statizoid

About this data

Indicator
Access to anti-retroviral drugs, male (%)
Unit
%
Source
UNAIDS estimates
Licence
CC BY 4.0 (World Bank Open Data)
Coverage
160 places, 3,923 data points, 2000–2024
Last refreshed

The percentage of adult males living with HIV who are receiving antiretroviral therapy.